Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on
Friday, November 23rd for the fiscal quarter ended September 30, 2018. The Company’s unaudited fiscal Q2 2019 condensed
interim consolidated financial statements and MD&A are available on SEDAR.
In addition, the Company has retained PCG Advisory Group (“PCG”) to increase its profile amongst retail brokers, high net worth
individuals and family offices in the United States. This investor relation activity will complement Antibe’s existing U.S.
coverage of institutional investors and sell side analysts. The agreement with PCG, which is subject to the approval of the TSX
Venture Exchange, has an initial term of 3 months and can be terminated by either party on 30 days prior notice. PCG will receive a
fee of US$6,500 per month. PCG is an investor relations firm based in New York, is independent of Antibe and does not have any
interest, directly or indirectly, in securities of Antibe or any right to acquire such interest.
The Company has also granted 40,000 restricted share units (“RSUs”) to a consultant pursuant to Antibe’s recently adopted RSU
plan.
About PCG Advisory Group
Founded in 2008, PCG Advisory is dedicated to the delivery of top-tier strategic advisory services that encompass investor and
stakeholder relations, capital markets navigation, corporate communications and social media management for emerging growth
companies. The team at PCG has extensive experience with life science, fintech and blockchain technology and works with innovative
and emerging companies from around the globe. As an aggregation, distribution, and engagement platform, PCG reaches thousands of
individual, retail and institutional investors and stakeholders in its proprietary and extensive distribution network, and through
the use of unique digital marketing and audience development techniques.
www.pcgadvisory.com.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a
safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent
global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products
servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of
knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries,
operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.
www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of
financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will",
"anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements
involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ
materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from
those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its
ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device
development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the
reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable
law.
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
(416) 473 4095
dan.legault@antibethera.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181123005257/en/